Patients with T2DM have been reported to exhibit elevated apolipoprotein B (ApoB) and non-esterified fatty acids (NEFAs) levels, as well as increased production and delayed catabolism of lipoproteins, for example, chylomicron, leading to postprandial hyperlipidemia [85,86,87]. Here, APOB is linked to hyperlipidemia.